Cerro al Volturno, Italy
Cerro al Volturno, Italy

Time filter

Source Type

Patent
Euticals Spa | Date: 2016-08-23

A cocrystal of tiotropium bromide and lactose monohydrate is herein disclosed. In the cocrystal the components tiotropium bromide and lactose are preferably present in an almost stoichiometric ratio. Said cocrystal has a single endothermic event at about 191-193 C. determined by DSC. A process for the preparation of the cocrystal is also disclosed. Preferably, the cocrystal has a particle size distribution of D90<10 m. The cocrystal is also disclosed for use as medicament, in particular for the treatment of a respiratory complaint, such as chronic obstructive pulmonary disease (COPD), bronchitis, emphysema and asthma. A pharmaceutical composition comprising the cocrystal as active ingredient is also disclosed, in particular for administration by inhalation. In the latter case, said cocrystal has a mean particle size of 0.5 to 10 m, preferably 1 to 6 m, more preferably 1.5 to 5 m.


A Rifaximin polymorphic mixture of / form in a relative ratio of 85/15 3 and a process for its preparation are herein disclosed. Said polymorphic mixture of Rifaximin is also disclosed for use as a medicament, in particular in the treatment of travelers diarrhea and hepatic encephalopathy. A pharmaceutical composition comprising said polymorphic mixture of Rifaximin as active ingredient, in particular a solid formulation, more in particular a film coated tablet are disclosed. A polymorphic form of crude wet rifaximin and of purified wet rifaximin and their use as intermediates in a process for the preparation of Rifaximin polymorphic mixture of / form in a relative ratio of 85/15 3 are also disclosed.


The present invention relates to a process for the preparation of aminoaryl- and aminoheteroaryl boronic acids and esters of formula (I) in high yields


The present invention relates to the biocatalyzed synthesis of enantiomerically pure (3R) and (3S)-methyl-1,2,3,4-tetrahydroquinoline. Said enantiomerically pure compounds are useful as chiral synthons in organic synthesis and, in particular, for the preparation of diastereomerically pure (21R) and (21S)-agratroban and its analogues. New compounds used as intermediates in the process of the invention are also disclosed.


The present invention relates to the biocatalyzed synthesis of enantiomerically pure (3R) and (3S)-methyl-1,2,3,4-tetrahydroquinoline. Said enantiomerically pure compounds are useful as chiral synthons in organic synthesis and, in particular, for the preparation of diastereomerically pure (21 R) and (21 S)-agratroban and its analogues. New compounds used as intermediates in the process of the invention are also disclosed.


Patent
Euticals S.P.A. | Date: 2015-09-02

A cocrystal of tiotropium bromide and lactose monohydrate is herein disclosed. In the cocrystal the components tiotropium bromide and lactose are preferably present in an almost stoichiometric ratio. Said cocrystal has a a single endothermic event at about 191-3C determined by DSC. A process for the preparation of the cocrystal is also disclosed. Preferably, the cocrystal has a particle size distribution of D90 < 10. The cocrystal is also disclosed for use as medicament, in particular for the treatment of a respiratory complaint, such as chronic obstructive pulmonary disease (COPD), bronchitis, emphysema and asthma. A pharmaceutical composition comprising the cocrystal as active ingredient is also disclosed, in particular for administration by inhalation. In the latter case, said cocrystal has a mean particle size of 0.5 to 10 m, preferably 1 to 6 m, more preferably 1.5 to 5 m.


Patent
Euticals S.P.A. | Date: 2014-03-12

Processes for preparing pimecrolimus starting from ascomycin, exploiting the selectivity characteristics of the purified enzymatic systems particularly regarding the selective deprotection of the hydroxyl groups present in position 33 of ascomycin. Such method represents the first example of chemoenzymatic synthesis for preparing pimecrolimus.


Patent
Euticals S.P.A. | Date: 2014-10-15

A process for the preparation of the amorphous form of Regadenoson of formula


A Rifaximin polymorphic mixture of / form in a relative ratio of 85/153 and a process for its preparation. The polymorphic mixture of Rifaximin is for use as a medicament, in particular in the treatment of travelers diarrhea and hepatic encephalopathy. A pharmaceutical composition comprises the polymorphic mixture of Rifaximin as active ingredient, in particular, a solid formulation, more in particular, a film coated tablet. A polymorphic form of crude wet rifaximin and of purified wet rifaximin their use are used as intermediates in a process for the preparation of Rifaximin polymorphic mixture of / form in a relative ratio of 85/153.


Patent
Euticals S.p.A. | Date: 2015-10-07

A process for the preparation of the amorphous form of Regadenoson of formula is disclosed together with new crystalline polymorphic forms E, F and G and methods for their preparation. Regadenoson amorphous form can be prepared in mild reaction conditions with high chemical purity (>99.6%) and high stability to the heating. A particularly thermodynamically stable anhydrous crystalline form of Regadenoson (form G) is also disclosed, provided with high stability not when exposed to 90% RH at 25 C. for 96 hour, but also to the heating up to 200 C.

Loading EUTICALS SpA collaborators
Loading EUTICALS SpA collaborators